Metric Deep Dive: Understanding Standard BioTools Inc (LAB) Through its Ratios

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $1.92 in the prior trading day, Standard BioTools Inc (NASDAQ: LAB) closed at $1.93, up 0.52%. In other words, the price has increased by $0.52 from its previous closing price. On the day, 4.98 million shares were traded. LAB stock price reached its highest trading level at $1.95 during the session, while it also had its lowest trading level at $1.85.


Our goal is to gain a better understanding of LAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.17 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.05.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.

On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.

On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 ’24 when Casdin Partners Master Fund, L bought 100,000 shares for $2.60 per share. The transaction valued at 260,000 led to the insider holds 46,075,821 shares of the business.

Casdin Partners Master Fund, L bought 150,000 shares of LAB for $387,735 on May 22 ’24. The Director now owns 45,975,821 shares after completing the transaction at $2.58 per share. On May 21 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 350,000 shares for $2.56 each. As a result, the insider paid 895,930 and bolstered with 45,825,821 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 714912512 and an Enterprise Value of 231135360. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.63 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 1.823 whereas that against EBITDA is -2.851.

Stock Price History:

Over the past 52 weeks, LAB has reached a high of $3.16, while it has fallen to a 52-week low of $1.57. The 50-Day Moving Average of the stock is -22.28%, while the 200-Day Moving Average is calculated to be -19.45%.

Shares Statistics:

The stock has traded on average 2.57M shares per day over the past 3-months and 2490020 shares per day over the last 10 days, according to various share statistics. A total of 369.92M shares are outstanding, with a floating share count of 363.85M. Insiders hold about 1.64% of the company’s shares, while institutions hold 72.00% stake in the company. Shares short for LAB as of 1715731200 were 12094800 with a Short Ratio of 5.15, compared to 1713139200 on 11277340. Therefore, it implies a Short% of Shares Outstanding of 12094800 and a Short% of Float of 6.68.

Most Popular